Patents by Inventor Ian Kirby

Ian Kirby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic combinations of OX40L antibodies for the treatment of GvHD
    Patent number: 9868789
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 16, 2018
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTIBODIES AND IMMUNOCYTOKINES
    Publication number: 20170362321
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 6, 2017
    Publication date: December 21, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170327586
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTIBODIES, USES & METHODS
    Publication number: 20170327587
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170260279
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 14, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Antibodies and immunocytokines
    Patent number: 9617338
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Antigen binding proteins to Oncostatin M (OSM)
    Patent number: 9605063
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Anti-hOX40L antibodies, uses, and methods
    Patent number: 9587030
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 7, 2017
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Antibodies, Uses & Methods
    Publication number: 20170044250
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Antibodies and immunocytokines
    Patent number: 9567399
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 14, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170037137
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Antibodies, Uses & Methods
    Publication number: 20170002083
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: September 8, 2016
    Publication date: January 5, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Antibodies, Uses & Methods
    Publication number: 20160368997
    Abstract: The present invention relates to anti-human OX4OL antibodies, new medical uses and methods.
    Type: Application
    Filed: March 3, 2015
    Publication date: December 22, 2016
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Synergistic combinations of OX40L antibodies for the treatment of GVHD
    Patent number: 9512229
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 6, 2016
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20160264675
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: April 29, 2016
    Publication date: September 15, 2016
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell, Leslie Susan Keen, Victor Tkachev
  • Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
    Patent number: 9434785
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: September 6, 2016
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac, Leslie Susan Kean, Victor Tkachev
  • ANIMAL MODELS AND THERAPEUTIC MOLECULES
    Publication number: 20160044900
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: June 25, 2015
    Publication date: February 18, 2016
    Inventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
  • Anti-human OX40L antibodies
    Patent number: 9234043
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: January 12, 2016
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • CD127 binding proteins
    Patent number: 9150653
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: October 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alexander H. Taylor, Thomas Matthew Webb, Yu Xue
  • Anti-human OX40L antibodies and methods of treatment
    Patent number: 9139653
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 22, 2015
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac